

Index

- 2D vs. 3D acquisitions, 269
- AATH model, 64
- abusive head trauma, 331, 333
- acetazolamide (Diamox), 116, 150, 152, 289
- acute coronary syndrome (ACS), 302, 306
- acute myocardial infarction (AMI), 303, 306, 308
- ADC. *See* apparent diffusion coefficient (ADC)
- adenosine perfusion MRI, 306
- adiabatic inversion, 42
- Alzheimer's disease, 116, 164–167, 171–172
- classification, 171, 173
- default mode network, 120
- differential diagnosis, 168, 170–171
- VASO imaging, 99–101
- amnesic MCI, 167
- amyloid, 99, 166
- anaplastic astrocytomas, 204, 210–211, 225
- ancillary testing, 179
- aneurysms, 146–150
- angina, 302–303, 306, 319
- angiogenesis, 204
- angiography, 1, 146, 163, 210, 325, *See also* coronary X-ray
- angiography (CXA), *See also* magnetic resonance angiography (MRA)
- catheter, 282
- CT, 282
- pulmonary, 292
- angioplasty, 148
- angiotensin II, 284
- angiotensin-converting enzyme inhibitor (ACE-I), 284
- anoxic brain injury (ABI), 187–190, 201
- anti-angiogenic therapies, 222, 336
- anti-vascular effects, 246
- anti-VEGF therapy, 245–247
- aphasia, 130, 133, 152, 168, 182
- apparent diffusion coefficient (ADC), 85, 100, 153
- in pediatrics, 328, 347
- area under the curve (AUC), 224
- arterial arrival time (AAT), 44, 108, 114–115, 117
- arterial blood volume (aBV), 38–39
- arterial blood water spins, 38
- arterial input function (AIF), 5–6, 17, 20, 220, 261
- and tissue concentration, 8
- ASL-MRI, 41
- DCE-MRI, 64, 68
- delay and dispersion, 31
- gradient echo sequences, 22–27
- partial volume effects, 36
- shape determination, 27
- spin echo sequences, 22
- SVD, 30
- tissue concentration curve, 29
- tracer kinetic model, 18–19
- arterial ischemic infarcts, 347
- arterial spin labeling (ASL)-MRI, 5, 38–48, 53
- advantages, 107, 195
- analysis techniques, 51
- brain death, 180
- brain function experiments, 110–111
- CBF, 5
- differential diagnosis, 170–171
- disadvantages, 108, 52
- evaluating response to treatment, 226
- experimental methods, 48
- in Alzheimer's disease, 165–167
- in aneurysms, 147
- in AVMs, 145
- in cardiac diseases, 312
- in cerebrovascular reactivity, 151
- in congenital heart disease, 333
- in FTLT, 168
- in hematoma, 187
- in kidneys, 285–288, 301
- in lungs, 293
- in MCI, 167
- in Moyamoya disease, 145
- in neurodegenerative disease, 164, 171–174
- in neuro-oncology, 223–226, 228–229
- in neuroscience, 104, 107–110
- in Parkinson's disease, 168
- in pediatric brain disease, 327–328, 330, 332, 334
- in pediatrics, 326–327, 336, 340–341
- in stroke, 129, 131, 138
- in TIA, 142
- in vasculitis, 182
- neurovascular coupling, 111–114
- pharmacological, 114–117, 120
- physiological parameters, 39
- protocols and sequences, 52–53
- pulmonary, 292
- quantification and modeling, 39–41
- readout methods, 49, 50
- vs. BOLD, 108
- vs. DSC-MRI, 341
- arterial transit artifact (ATA), 52, 136
- arterial transit time (ATT), 39
- arterial tree, 18, 20
- arterial water magnetization, 42
- arterial water spins, 41
- arteriovenous malformations (AVMs), 127, 145–147, 163
- ASE approach, 77, 82
- ASL-MRI. *See* arterial spin labeling (ASL)-MRI
- astrocytomas, 204, 210–212, 225, 233
- juvenile pilocytic, 335–336, 338
- oligodendrogliomas and, 232
- atherosclerosis, 45, 282, 309
- aura, 185, 191
- auto-immune necrotizing encephalitis, 181
- autoregulation dysfunction, 184, 187
- autoregulation of coronary circulation, 304
- background-suppression techniques, 51
- baseline subtraction method, 207
- baseline T₁ mapping sequence, 260
- benign vs. malignant lesions, 239, 247, 256, 258
- bevacizumab, 226, 245, 336
- bi-dimensional measurement, 266–267
- biomarkers, 244–246
- predictive and prognostic, 244, 246
- biopsy
- in pediatric tumors, 335

Index

- biopsy (cont.)
 in prostate cancer, 243
 neuro-oncology, 211, 218, 224–225, 236
- BIRADS scoring system, 240
- blood flow f , 39
- blood flow imaging, 1–12
- blood perfusion, 62, 74
- blood plasma concentration c_p , 60
- blood pool agents, 17, 33–34, 293
- blood volume V , 39, 283
- blood–brain barrier (BBB)
 disruption, 32–33
 DSC-MRI, 32
 in multiple sclerosis, 195
 in neuro-oncology, 205, 221
 in stroke, 140
 VASO imaging, 99
- blood–brain partition coefficient, 40
- body transmit coil, 67
- BOLD MRI, 16, 75–77
 in cardiac disease, 312
 in cerebrovascular reactivity, 152
 in kidneys, 288–290
 in neuroscience, 105–107, 111–114, 116–118
 in seizures, 183
 VASO imaging, 91, 95, 97
 vs. ASL, 108
- bolus arrival time (BAT), 38–39, 52
- bolus passage perfusion, 63
- bolus PWI, 142, 145, 150
- bookend technique, 31
- borderzone areas, 44
- borderzone sign, 142
- brain atrophy, 165–166, 171, 173
- brain death, 179
- brain function
 and hemodynamic activity, 103, 106
 ASL-MRI, 110–111
 BOLD MRI, 105
- brain oxygenation, 75, 82, 85
 experimental methods, 77–85
 theory, 75–77
- brainstem gliomas, 337
- brain tissue signal measurement, 27–29
- brain tumors. *See also* neuro-oncology
 DCE-MRI, 341
 DSC-MRI, 33
 pediatric, 334–337, 345
 VASO imaging, 99–100
- BRCA1/2, 240
- breast cancer, 239–241, 255–285
 case studies, 277, 279
 DCE-MRI, 67, 256–259
 MRI artifacts, 271
 neoadjuvant therapy, 265–268
- objective treatment response
 categories, 266
- pharmacokinetic modeling, 260–265
- texture analysis, 247
- breast vascularity score, 259–261
- brivanib, 245
- bvFTD, 168, 170–171, 178
- caffeine, 116
- cancer. *See also specific cancers, See also oncology*
 DCE-MRI, 59
 radiation exposure, 308
- capillary morphology, 214
- capillary permeability, 205, 216, 221, 234
- captopril, 284, 286
- carbon dioxide administration, 116
- cardiac diseases, 302
 case studies, 319, 322, 324
 clinical background, 302–305
 congenital heart disease, 333–334, 340
 MR applications, 314
 perfusion imaging vs. other modalities, 306–313
 perfusion MRI studies, 305–306
 protocols and analyses, 313–315
- cardiac masses, 306
- cardiac output, 2, 180
- cardiac tumors, 306
- carotid endarterectomy (CEA), 142, 191, 194, 202
- carotid stenosis, 116, 127, 142, 191, 202
- catheter angiography, 282
- cell death, 328
- central volume principle, 2–5, 283
 and Kety–Schmidt technique, 8
 applications of, 6
 freely diffusible indicators and intravascular agents, 5
- centrifugal pattern, 259–260
- centripetal pattern, 259–260
- cerebral abscess, 195
- cerebral autoregulation, 128
- cerebral blood flow (CBF), 1, 7, 11, 39, 205
 age-related, 326
 ASL-MRI, 5, 38, 50
 brain death, 180
 DSC-MRI, 19
 early measurements, 16
 functional connectivity, 117–120
 gender-related, 180
 in anoxic brain injury, 201
 in diabetes, 116
 in hypercapnia, 190
- in neuro-oncology, 224
- in neuroscience, 103, 105, 107, 110–114, 117
- in pediatrics, 187, 340
- in stroke, 128–129, 140
- Kety–Schmidt technique, 7
- MR-measured, 84
- cerebral blood volume (CBV), 11, 16, 39
 blood pool agents, 34
 calculation, 207, 227
 contrast agent leakage, 33
 DSC-MRI, 19
 in neuro-oncology, 210, 212, 215
 in neuroscience, 111–112, 114
 in pediatric tumors, 336
 measurements, 77–78
 non-invasive evaluations, 89–98
 quantification of absolute CBV, 91–92, 94–96, 98–99
 SSC imaging, 34
 VASO imaging, 89, 100
 venous, 77–79, 82
- cerebral circulation time (CCT), 148
- cerebral edema, 181
- cerebral ischemia, 84
- cerebral oxygen metabolic index (COMI), 75, 83–84
 applications, 84–85
- cerebral perfusion. *See* cerebral blood flow (CBF)
- cerebral perfusion pressure (CPP), 75, 187
- cerebral rate of oxygen metabolism (CMRO₂), 76, 83, 111–112, 116
- cerebral vascular resistance (CVR), 187
- cerebral volume loss, 180
- cerebrovascular autoregulation, 75–76
- cerebrovascular disease, 113
- cerebrovascular reactivity, 150–152
- cerebrovascular reserve, 152, 190
- challenge paradigms, 34
- chemical shift artifacts, 271
- cirrhosis, 290–291
- clinical trial endpoint, 222
- CNS infections, 185
- CNS lymphoma, 225
- collateral blood flow, 138–140
- color map, 262–264
- colorectal liver metastases, 245, 247, 253
- combined DSC-ASL, 180
- combined DSC-DCE, 223
- combined PWI-ASL, 153
- compartmental modeling, 262
- compartmentalization, 27, 33

- computed tomography (CT).
See also SPECT
 angiography, 282
 dynamic perfusion, 16
 early studies, 1
 EBCT, 283
 in liver metastases, 242
 in neurovascular disease, 152
 in pediatric brain, 326
 MDCT, 290
 pulmonary, 292
 xenon, 8–9, 129
- computer-assisted diagnosis (CAD),
 260–265, 270
 in breast MRI, 265
- concentration–time curve (CTC),
 17–18, 206–207, 283–284
- congenital heart disease (CHD),
 333–334, 340
- continuous ASL (CASL), 41, 43,
 46–47, 51
 cerebral volume loss, 180
 in neuroscience, 107, 119
- contrast agents, 208, *See also*
 paramagnetic contrast agents, *See*
also MR contrast agents, *See also*
 gadolinium
 DCE-MRI, 67
 disadvantages of using, 103
 hyperpolarized, 312
 leakage, 32–33, 207–209
 power injection, 227
 recirculation, 206–208
- contrast-enhanced ultrasound
 (CEUS), 283
- contrast-based VASO imaging, 91–92,
 94–96, 98–99
- contrast-to-noise ratio (CNR), 108
- convolution, 5–6, 19–20, 40
- coronal-sagittal oblique methods, 64
- coronary angiography, 325
- coronary artery bypass grafting
 (CABG), 319, 322
- coronary artery disease (CAD),
 302–303, 311, 325
 analysis techniques, 313
 endothelial function, 309
 ischemia testing, 305–306
 perfusion MRI, 308
 time course, 302
- coronary flow reserve (CFR), 304, 309
- coronary perfusion, 304–305
- coronary sinus (CS), 309–310
- coronary stenosis, 305–306, 308–309,
 311, 319, 322, 325
- coronary stents, 313
- coronary X-ray angiography (CXA),
 303, 305, 308, 319, 322
- cortical depth, 111
- cortical edema, 191, 201, 333, 337
- covariance patterns, 174
- Creutzfeldt–Jakob disease (CJD), 186
- crusher gradients, 46, 51, 182
- cumulative density function, 4
- cumulative distribution function, 4
- DCE-MRI. *See* dynamic contrast-
 enhanced MRI (DCE-MRI)
- deconvolution, 19, 29–31, 51
 in stroke, 130
- default mode network (DMN), 120
- DEFUSE trial, 134, 137
- delay times, 138, 287
- delayed compliance model, 112
- de-noising techniques, 50
- deoxyhemoglobin (dHb), 76,
 105, 112
- diabetes, 116, 303
- dielectric resonance, 66
- diffuse intrinsic pontine gliomas
 (DIPG), 337
- diffusion gradients, 51
- diffusion length, 29
- diffusion narrowing regime, 28–29
- diffusion tensor MRI, 171, 331
- diffusion-weighted imaging (DWI),
 128–129, *See also* diffusion-
 perfusion mismatch
 in neuro-oncology, 224
 in oncology, 238
 in prostate tumors, 243
 in stroke, 153
- diffusion-perfusion mismatch,
 127–134, 136, 160, 162
 challenges to, 137–138
 in pediatrics, 330
 in TIA, 142
 in vasospasm, 148
- Dirac delta function, 5, 8
- disseminated intravascular
 coagulation (DIC), 200
- dobutamine stress MRI, 303–305,
 313–314
- DSC-MRI. *See* dynamic susceptibility
 contrast (DSC)-MRI
 dual echo imaging, 23, 207,
 dural arteriovenous fistula (dAVF),
 127, 145–146, 148
- DWI. *See* diffusion-weighted imaging
 (DWI)
- dye dilution, 3
- dynamic contrast-enhanced MRI
 (DCE-MRI), 59–74
 AIF measurements, 25
 anti-vascular effects imaging, 245
 artifacts, 271
 chemotherapy response and, 241
 fixed and free parameters, 74
- hardware, software and scanning,
 268–272
- image acquisition, 64–68
- image analysis, 68–71
- in breast cancer, 239, 255–256
- in clinical trials, 267
- in kidneys, 284–285
- in liver, 241
- in malignant breast lesions, 239
- in neuro-oncology, 222–223, 228
- in oncology, 238, 242, 244
- in pediatrics, 341
- modeling, 59–64
- pharmacokinetic modeling,
 260–265, 268
- prostate tumors, 242–243
- screening in high-risk populations,
 240
- semi-quantitative and qualitative,
 256–259
- staging local-regional disease, 240
- dynamic CT perfusion (CTP), 16
- dynamic nuclear polarization (DNP),
 312
- dynamic scan time, 29
- dynamic series, 261
- dynamic susceptibility contrast
 (DSC)-MRI, 11, 16–35
 acquisition optimization, 29
 basic equation, 19
 benefits, 195
 blood–brain barrier disruption,
 32–33
 brain death, 180
 deconvolution, 29–31
 delay and dispersion, 31
 in neuro-oncology, 205–218,
 226–228
 in pediatrics, 326, 328, 334, 338–340
 in stroke, 129, 131
 methodology, 17
 MR contrast agents, 21–22
 MR signal to contrast agent
 concentration, 22–29
 qualitative imaging, 31
 recalibration, 31
 T₁ effect, 32
 tracer kinetic model, 18–21
 vessel size imaging, 31
 vs. ASL, 341
- dyspnea, 303, 324
- echo time (TE), 66, 91, 108–109
 in BOLD, 106
- echocardiography, 303, 306
- echo-planar imaging (EPI)
 ASL-MRI, 49
 BOLD-MRI, 107
 in neuro-oncology, 226

Index

- echo-planar imaging (EPI) (cont.)
 multi-slice or gradient, 48
 single-shot, 29
 VASO, 97–98
 echo-shifting, 29
 EES. *See* extravascular extracellular space
 electrocardiography, 319
 electron beam CT, 283
 electron paramagnetic resonance (EPR), 289
 encephalitis, 181, 195
 end of the bolus, 44–45
 endothelial function, 309–310
 enhancement pattern, 259–260
 epilepsy, 192, 331, 335
 EPISTAR, 43–44
 EPITHET trial, 135, 137
 Ernst-angle, 32
 executive dysfunctional MRI, 167
 EXTEND trial, 137
 external-beam radiation therapy (EBRT), 214, 217
 extra-arterial AIF measurement, 27
 extracranial-to-intracranial (EC-IC) bypass, 142, 150
 extravasation, 99, 339
 extravascular extracellular space (EES), 59–60, 220–221, 262
 in breast cancer, 268
 in tumor cells, 256

 Fahraeus effect, 62
 FAIR, 43–44, 52, 228
 false positives, 179, 240, 265
 fat suppression vs. subtraction, 269–270
 ferumoxytol, 21, 34
 fibrillary astrocytomas, 210–211, 233
 fibroadenoma, 279
 fibrosis, 291
 Fick principle, 2, 6
 fit failures, 69–70
 FLAIR imaging, 181, 192, 217
 flip angle, 32–33, 60, 74
 accuracy, 67
 gradient echo sequences, 66
 optimization, 66
 setup procedure, 67
 variable method, 67
 flow heterogeneity, 140
 flow indicator, 2
 flow-no-reflow phenomenon, 128, 138
 focal arterial ischemic strokes, 328–329
 focal hyperperfusion, 180, 190–195
 focal hypoperfusion, 144, 180–187
 fosbretabulin, 245

 Fourier transform, 30, 51
 fractal analysis, 247
 fractional volume v_e , 59–62, 67, 69, 71
 freely diffusible indicators, 5–7
 freons, 7, 12
 frequency function, 4
 frontotemporal lobar degeneration (FTLD), 164, 168–170, 178
 functional connectivity, 117–120
 functional MRI (fMRI)
 BOLD technique, 105–107, 111–114
 in ASL, 107–110
 rs-fMRI, 117, 165
 USPIO enhanced, 34–35
 VASO imaging, 91–95, 97
 furosemide, 289–290

 GABA, 106, 117–118
 gadobenate dimeglumine, 21, 272
 gadodiamide, 21
 gadofosveset trisodium, 17, 21, 34
 gadolinium, 11, 16, 21
 brain oxygenation studies, 78
 DCE-MRI, 59
 in breast cancer studies, 272
 in pediatrics, 338
 plasma half-life, 33
 T_1 effect, 32
 gadolinium chelates, 21, 283–284, 293
 gadolinium concentration, 63
 MRI signal, 60
 pharmacokinetic modeling, 60–64
 gadolinium-DTPA, 21, 91, 94, 286,
 See also Magnevist
 gadoterate meglumine, 21
 gadoteridol, 21
 gadoversetamide, 21
 gadubutrol, 21
 gamma variate function, 31, 207–208, 227
 Gaussian process deconvolution, 30
 General Electric, 52
 general kinetic model, 41
 GESSE. *See* MEGESE
 Gleason score, 243
 glioblastoma multiforme (GBM), 204, 206, 210–211, 214, 216, 218, 222, 224–225, 236
 glioma grading, 210–212, 221, 224–225
 gliomas, 99, *See also* low-grade gliomas,
 See also high-grade gliomas
 brainstem, 337
 global hyperperfusion, 180, 187–190
 global hypoperfusion, 144, 179–181
 glomerular filtration rate (GFR), 282, 284, 290, 301
 gradient echo sequences, 22–29, 31, 153
 BOLD effect, 76
 brain oxygenation, 82
 flip angles, 66
 in pediatrics, 339, 341
 spoiled, 59
 gradient-echo EPI, 48
 GRAPPA technique, 271
 GRASE technique, 48–49, 52, 94, 97
 gray matter loss, 171–172, 180
 gray-white matter differentiation (GWMD), 201

 heart-lung vascular system, 6
 Heidenhain variant, 186
 hemangioblastoma, 226
 hematocrit, 18, 22, 60, 62, 74
 hematoma, 186
 hemodynamic activity, 111, 118
 and brain function, 103, 106
 in Alzheimer's disease, 166
 hemoglobin, 76
 hepatic artery, 290
 hepatic perfusion index (HPI), 242
 hepatitis C, 291
 heuristic methods, 64
 high-grade gliomas, 204, 210–211, 215, *See also* glioblastoma multiforme (GBM)
 intracranial metastases and, 214, 234
 meningiomas and, 221
 radiation necrosis and, 214–217, 221
 TDL and, 218
 high-risk population screening, 240
 histograms, 70
 histopathology, 205, 211, 215
 hormone replacement therapy (HRT), 309–310
 hybrid MR/PET scanners, 79
 hypercapnia, 76–80, 83
 global hyperperfusion, 190
 hyper-dynamic cardiovascular states, 187
 hyperemia, 304, 309, 312, 314
 hyperperfusion
 focal, 180, 190–195
 global, 180, 187–190
 in Alzheimer's disease, 166–167
 in MCI, 167
 pediatric, 327–329, 341
 hyperpolarized contrast agents, 312
 hypertension, 281–282
 hypoperfusion, 142–145
 focal, 180–187
 global, 179–181
 in Alzheimer's disease, 165–167, 172
 in FTLD, 168–169
 in MCI, 167
 in Parkinson's disease, 168
 pediatric, 328, 330

- hypothermia treatment, 328
hypoxia, 76–77, 79–80, 83
 medullary, 289, 299
hypoxic ischemic injury (HII),
 327–328
- IBMC trial, 269
implanted cardioverter-defibrillators
 (ICDs), 313
in vivo blood oxygenation, 76
indicator concentration, 8–12
indicator detection pairs, 8
indicator dilution, 3
indicator dilution experiments, 4
indicator dilution theory, 2, 39, 63
indomethacin, 116
infarcts, 130, 330, 347
infections, 185
inflow vascular space occupancy
 (iVASO), 113
initial area under the curve (IAUC),
 223, 262
input functions
 blood flow imaging, 5–6
instantaneous injection, 18–20
inter-ictal phase, 183–184
interpolation, 28
intra-arterial AIF measurement,
 22–27
intra-axial metastases, 204, 224–225
intracranial abscess, 185
intracranial aneurysm rupture, 182
intracranial hematoma (ICH), 186
intracranial hemorrhage (ICH), 130,
 135
intracranial metastases, 204, 214, 219,
 225, 234
 radiation necrosis and, 216
intracranial pressure (ICP), 113, 187
intra-ductal carcinoma, 240
intravascular agents, 5
intravascular paramagnetic contrast,
 220–221
inversion time (TI), 41, 90, 96–97
iodinated contrast agent, 8, 10
iopamidol, 10
iron oxide, 21, 34, 284
ischemia, 84, 153, 307, 322
 arterial infarcts, 347
 myocardial, 302–303
 transient attack, 127, 141–142, 162
ischemia burden, 303, 306
ischemia testing
 acute coronary syndrome, 306
 coronary artery disease, 305–306
 principles of, 306–308
- Japanese EC-IC bypass trial (JET), 150
jugular bulb oximetry, 79
jugular vein, 80–81
juvenile pilocytic astrocytomas (JPAs),
 335–336, 338
- Kety–Schmidt technique, 6–8, 40
kidneys 281–290, *See also renal entries*
 ASL-MRI, 285–288, 301
 BOLD MRI, 288–290
 DCE-MRI, 63, 65, 288–290
 kidney disease, 21, 299
 perfusion imaging, 282–284
 vascular imaging, 282
kinetic curve, 256–257
 K^{trans} . *See* transfer constant K^{trans}
- labeling schemes, 42–48
late-gadolinium enhancement (LGE),
 303, 306, 314
leakage
 capillary, 61
 contrast agent, 32–33, 207–209
least squares solution, 69
Lewy body dementia (DLB), 164, 170
lithium phthalocyanine (LiPc), 289
liver, 290–292
liver lesion characterization, 241
liver metastases, 241–242, 245, 247,
 253
longitudinal relaxation, 32
longitudinal relaxivity, 59
Look-Locker readout, 45, 52
low-grade gliomas, 204, 210–211
 differentiating, 212–214
lungs, 292–293
luxury perfusion, 133, 181
- MAGIC sequence, 93
magnetic field inhomogeneities, 28,
 227
magnetic field strength, 97, 107, 268
magnetic resonance angiography
 (MRA), 47, 146, 163,
 See also diffusion-perfusion
 mismatch
 brain death, 179
 in cardiac diseases, 310
 in kidneys, 284–285, 288
 phase-contrast, 309
 pulmonary, 292
magnetic resonance arteriography, 292
magnetic resonance renography, 284,
 286
magnetic resonance spectroscopy
 (MRS), 117, 243, 331
magnetic resonance venography, 292
magnetic resonance (MR) perfusion
 imaging, 1, 12, 179,
 See also individual imaging
 techniques
- biopsy site, 236
in cardiac diseases, 303, 305–308,
 314
in kidneys, 283–284
in pediatric brain, 337
interpreting, 195
pediatric protocols, 337–342
protocol recommendations, 313
magnetic susceptibility, 24, 83
magnetization transfer (MT) effect, 42
magnetoencephalography (MEG), 332
Magnevist, 21, 59, 67,
 See also gadolinium-DTPA
major adverse cardiac events (MACE),
 303
malignant breast lesions, 239, 256
malignant mismatch, 135
malignant vs. benign lesions, 239, 247,
 256, 258
MARIBS study, 240
maximum-intensity projections
 (MIPs), 47, 259, 261
maximum-likelihood maximization-
 estimation method, 30
Maxwell equations, 24
McDonald criteria, 195
mean arterial pressure (MAP), 75, 187
mean transit time (MTT), 11, 18, 31,
 85, 283
 in stroke, 129
 in TIA, 142
medulla, 282
medullary hypoxia, 289, 299
MEGESE, 77–78, 82
MELAS, 337
meningiomas, 204, 221
meningoencephalitis, 195
MERCi clot retriever, 130, 132, 160
metabolic disorders, 333
metabolic pathway, 111
metabolic stressors, 255
middle cerebral artery (MCA), 22
middle cerebral artery occlusion
 (MCAO), 84
migraine, 185, 191, 193
mild cognitive impairment (MCI),
 167–168
misery perfusion, 76, 82
mitochondrial disorders, 333
Monte Carlo simulations, 28
motion artifacts, 50–51, 228, 313
 DCE-MRI, 66, 68, 271
motion correction, 50
Moyamoya disease, 127, 138, 144–145
MR contrast agents, 21–22
 acquisition optimization, 29
 blood–brain barrier, 32–33
 concentration, 22–29
 deconvolution, 29–31

Index

- MR contrast agents (cont.)
 renal failure, 16
 tracer kinetic model, 18–21
- MR signal
 formation, 27–29
 gadolinium concentration, 60
 intensity, 22–29
 phase, 24–25
- MR-IMPACT studies, 305, 308
- MTT. *See* mean transit time
- multi-compartmental analysis, 12
- multi-delay ASL, 45
- multi-detector CT (MDCT), 283, 290
- multi-focal disease, 240
- multiple sclerosis, 61, 193–196
- multi-slice EPI, 48
- multivariate statistics, 174
- myocardial ischemia, 302–303
- negative enhancement integral,
 207–208, 227
- negative predictive value (NPV),
 256–257
- neoadjuvant chemotherapy, 241,
 265–268
- nephrogenic systemic fibrosis (NSF),
 16, 21, 227, 284, 292
- neurodegenerative disease, 164–166
 ASL-MRI, 171–173
 developments, 173–174
 differential diagnosis, 170–171
 MR applications, 165–171
- neuronal activity, 103, 105–106, 111
- neuro-oncology, 204–226
 ASL-MRI, 223–226, 228–229
 case reports, 232, 234, 236
 DCE-MRI, 219–223, 228
 DSC-MRI, 205–218, 226–228
- neuroscience imaging, 103–120
 applications in, 111–120
 ASL-MRI, 107–111
 BOLD MRI, 105–107
- neurotransmitter pathway, 111
- neurovascular coupling, 111–114
- neurovascular disease, 38, 46, 51,
 127–128, 131–154
 limitations of treatment, 152–153
 perfusion studies, 128–152
 recommended protocols,
 153–154
- NIH stroke scale (NIHSS), 130–131,
 160
- nitric oxide, 309, 311
- nitrous oxide, 6–7, 40, 309, 311
- NSTE-ACS, 303, 306
- NSTEMI, 303, 306
- oligemia, 128, 137
- oligodendrogliomas, 204, 210–212, 232
- Omniscan, 21, 78
- oncology, 238–247, *See also* cancer,
See also neuro-oncology
 advanced image analysis, 246–247
 case study, 253
 conventional clinical practice, 238–244
 research applications, 244–246
- onset time of the bolus, 68
- Optimark, 21
- oxygen concentration in the blood, 2
- oxygen extraction fraction (OEF), 76,
 79–82
 in stroke, 82, 141
 PET- vs MR-based, 83
- oxygen metabolic image (OMI), 141
- oxygenation measurements, 75–76, 82,
 140
- oxyhemoglobin (HbO₂), 105
- pacemakers, 313
- PAH plasma clearance, 287–288
- pan-necrosis, 333, 347
- parallel imaging, 270
- paramagnetic contrast agents, 8, 11,
 220–221, 338
- Parker blood function, 68–69
- Parkinson's disease, 168
- partial volume effects, 50–51
 AIF, 25–27, 36
 DCE-MRI, 65
 in Alzheimer's disease, 165–166
- peak enhancement, 262
- peak height (PH), 205, 214–215
- peak percentage enhancement, 256
- pediatric brain, 326–341
 case studies, 345, 347
 developmental disorders, 334
 epilepsy, 331
 hyperperfusion, 187, 327–329, 341
 injury, 327–331
 normal development, 326–327
 perfusion protocols, 337–342
 tumors, 334–337, 345
- penumbra of ischemic tissue, 128–130,
 137–138
- percentage enhancement, 256, 258
- percentage of signal intensity recovery
 (PSR), 204–205, 214–216
- percutaneous coronary interventions
 (PCI), 303, 319, 325
- perfusion, 39, 62, 205
- perfusion imaging, 62,
See also magnetic resonance
 (MR) perfusion imaging
- perfusion rate *f*, 287
- pericardial effusion, 306
- peri-ictal phase, 190, 192
- peritumoral vasogenic edema, 214, 224
- periventricular leukomalacia (PVL), 333
- permeability imaging, 61
- permeability measurement, 140, 341
- permeability surface area product
 (PS), 61, 63
- persistently enhancing curve, 257–259
- pharmacokinetic modeling, 60–64,
 220–222, 239, 260–265
 in breast cancer, 268, 270
- pharmacological ASL, 114–117, 120
- phenolphthalein, 3
- Philips, 52
- pilocytic astrocytoma, 211–212
- pimonidazole, 289
- pixel mapping, 69, 71
- plasma flow, 18
- plateau curve, 257–259
- PNET, 336, 339, 345
- portal vein, 290
- positive predictive value (PPV),
 256–257
- positron emission tomography (PET),
 1, 10, 75, 79, 83, 103, 110, 114
 H₂O¹⁵-PET, 153
 in cardiac diseases, 303, 307–308
 in kidneys, 287
 in neurodegenerative disease, 164,
 168, 170, 174
 in pediatric brain, 327
 in stroke, 129
- post carotid endarterectomy
 syndrome, 191, 194
- posterior reversible encephalopathy
 syndrome (PRES), 184–185, 188,
 191
- post-stimulus undershoot, 112–113
- power injector, 227, 338
- pre-bolus approach, 33
- predictive biomarkers, 244, 246
- pre-enhancement images, 227
- primary breast tumors, 239–241
- primary vasculitis, 182
- primitive neuroectodermal tumors
 (PNET), 335
- principle component analysis, 32, 71
- prion disease, 186
- probability density function, 4
- prognostic biomarkers, 244, 246
- progressive non-fluent aphasia
 (PNFA), 168
- prostate tumors, 69, 242–244
- prostate-specific antigen (PSA), 242
- proximal artery occlusion, 137, 142, 152
- pseudo-permeability effect, 221
- pulmonary angiography, 292
- pulmonary embolism (PE), 292–293
- pulsed ASL (PASL), 41, 43–45, 51–52
 in neuro-oncology, 224, 228
 in neuroscience, 107
 in pediatrics, 340

Index

- pulsed-continuous ASL (pCASL), 43, 47, 51–52
 in neuro-oncology, 228
 in neuroscience, 107, 110
 in pediatrics, 334, 340
- Q2TIPS, 45, 50–52
 qualitative perfusion imaging, 31
 quantitative BOLD (qBOLD), 75–77
 quantitative MRI techniques, 31, 58
 quantitative susceptibility mapping (QSM), 75, 82–83
 QUASAR sequence, 44, 51–53
 QUIPSS (I and II), 45, 50–51, 111
 QUIXOTIC method, 83
- R_2 measurements, 17, 77–79
 R_2^* images, 289
 radiation exposure, 308
 radiation necrosis, 204, 214–217, 221
 in intracranial metastases, 216, 219
 in pediatric tumors, 336
 radiofrequency pulses. *See* RF pulses
 rate constant k_{ep} , 58–59, 61, 67
 recanalization, 138
 RECIST criteria, 59, 244, 266–267
 remifentanyl, 115–116
 remote insult, 187
 renal artery stenosis (RAS), 282, 284–286, 288, 290
 renal blood flow, 284, 292
 renal cell carcinoma metastasis, 226
 renal clear cell (RCC) cancer, 246
 renal clearance, 207
 renal cortex, 288
 renal dysfunction, 16, 21
 renal ischemia, 281, 284
 renal plasma flow (RPF), 284, 287–288
 renal scintigraphy, 284
 renal transplant, 290, 301
 renovascular disease (RVD), 282, 284
 reperfusion, 130–131, 134, 136
 vs. recanalization, 138
 repetition time (TR), 90, 92–94
 resection, 335
 residuals, 69
 residue function, 4, 6, 8, 16, 31, 40
 blood–brain barrier, 32
 MR contrast agent, 19
 scaling factor, 18
 resting-state fMRI (rs-fMRI), 117, 165
 revascularization, 191, 282, 303, 319
 reversible cerebral vasoconstrictive syndrome (RCVS), 182–183
 RF pulses
 ASL, 41–43, 48
 VASO imaging, 90
 rheumatoid arthritis, 70
 Rician noise distribution, 24
 rigid-body method, 95
 ROC curve analysis, 240, 243
 ROI (regions of interest) data, 65, 69, 71, 239
 root-mean-square residual, 69
- sagittal vs. axial imaging, 269
 sampling error, 205, 211, 224
 sampling location, 4
 sampling points, 5
 scar tissue, 303
 second impact syndrome, 331
 secondary vasculitis, 181
 seizures, 181, 183–184, 226
 focal hyperperfusion, 190–191
 SENSE technique, 270
 sequence parameters, 64
 shunt fraction, 146
 shunt lesions, 127, 145–146, 148
 sickle cell anemia, 187, 189
 Siemens, 52
 signal-to-noise ratio (SNR), 12
 ASL, 41, 228
 blood pool agents, 34
 in stroke, 130
 VASO imaging, 98
 simultaneous spin- and gradient echo (SAGE), 139
 single compartment Kety equation, 40
 singular valve decomposition (SVD), 30
 sorafenib, 246
 spatial registration, 68, 70
 spatial resolution, 94, 98, 270–271, 308, 313
 specific absorption rates (SAR), 340
 specific flow (f), 7–8, 11
 SPECT, 8, 110
 in cardiac diseases, 303, 305, 307–308
 in neurodegenerative disease, 164, 168, 170–171
 in pediatric epilepsy, 332
 in seizures, 183
 Spetzler-Martin criteria, 145
 spin echo sequences, 22, 28, 31
 spiral readouts, 48, 50
 spoiled gradient echo sequence, 59, 228
 spongiform encephalopathy, 186
 spreadsheets, 69, 71
 standard kinetic model, 41
 STAR labeling pulse, 46
 static dephasing regime (SDR), 28–29
 statistical inference methods, 30
 status epilepticus, 191–192, 335
 steady-state free precession (SSFP), 48
 steady-state susceptibility contrast (SSC) imaging, 16, 21, 33–35
- STEMI, 302, 306
 stenosis, 116, 127, 142, 191, 202,
See also coronary stenosis
 stereotactic radiosurgery, 216, 219, 226
 stress ECG, 303, 319
 stress-only tests, 304–305
 stress perfusion MRI, 314, 319, 322
 stress-rest tests, 304–305, 312
 stroke, 85, 127–145
 and seizures, 191
 case study, 160
 choice of treatment, 152
 collateral assessment, 138–140
 COMO values, 85
 diffusion-perfusion mismatch, 128–133, 137–138
 flow–no-reflow phenomenon, 138
 focal arterial ischemic, 328–329
 focal hypoperfusion, 181
 MRI, 133–137, 153
 OEF values, 82
 perfusion markers showing penumbra, 129–130
 post-processing PWI, 130
 triage, 130–133
 structural MRI, 168, 171, 173
 subarachnoid hemorrhage (SAH), 148, 182
 subcortical ischemic vascular dementia (SIVD), 170
 subtraction imaging, 269–270
 sunitinib, 246
 superior sagittal sinus, 80–81, 83
 support vector machine algorithms, 174
 surgical bypass
 hypoperfusion, 142–145
 susceptibility artifacts, 268, 271, 315, 340
 susceptibility contrast MRI, 16–35
- T_1 effect, 32–33
 T_1 mapping sequence, 260
 T_1 relaxation effect, 207, 209, 340
 T_1 values, 89–91, 96
 kidneys, 287
 magnetic field strengths, 97
 T_1 -weighted imaging, 209–210, 220, 228, 238, 241, 244
 T_2^* -weighted images, 76–77, 206, 244, 289
 T_2 -weighted scanning, 17
 temporal resolution, 109, 270–271
 territorial ASL, 47
 therapeutic biomarkers, 244
 three time points (3TP) analysis, 262

Index

- thrombi, 306
time constant heart-lung system, 6
time–intensity curve. *See* kinetic curve
time-is-brain, 128, 138
time to peak (TTP), 17–18
 in breast cancer, 239
 in stroke, 129
 in vasospasm, 148
tinnitus, 146, 148
tissue blood flow, 1
tissue concentration curve, 29
tissue homogeneity model (THM),
 5, 64
tissue oxygenation, 288–289
tissue response function. *See* residue
 function
tissue signal measurement, 27–29
tissue T_1 value (T_{10}), 67, 91
 $T_{\max}$, 129
Tofts model, 60–63, 67–69
 $TP53$, 240
tPA, 127–128, 130–132, 134–135
tracer kinetic model, 18–21, 31–32, 283
transcranial Doppler (TCD), 148
transfer constant K^{trans} , 59–62, 67, 71,
 219, 221, 223, 228, 261
 anti-vascular effects, 245
 in breast cancer, 241, 267–268
 in oncology, 245
transfer-insensitive labeling (TILT)
 pulse, 46
transient ischemic attack (TIA), 127,
 141–142, 162
transient symptoms with infarct, 141
transit times, 4, 44–45
 mean transit time, 11, 18
transport function, 4, 6
transverse relaxation rates,
 27, 32
transverse relaxation time, 22, 27,
 75–76
treadmill exercise test, 303
TRUST method, 75, 83, 117
tuberous sclerosis complex, 336
tumefactive demyelinating lesions
 (TDLs), 204, 216–218, 220
tumor angiogenesis, 204–205, 209
tumor grade, 99, 204, 213, 221, 335
tumor progression, 336
tumor recurrence, 336
tumor size, 266–267
tumor spatial complexity, 247
tumor sub-regions, 247
tumor vessels, 255
tumor-mimicking lesion, 210, 220
two-compartment exchange model
 (2CXM), 63, 70
tyrosine kinase inhibitors, 245, 247

ultrasmall superparamagnetic iron
 oxide (USPIO), 34, 284
ultrasound, 282–283
uni-dimensional measurement,
 266–267
unilateral vs. bilateral
 acquisition, 268
unilateral-increased vascularity, 259,
 261
upslope technique, 313

variable flip angle method, 67
vascular endothelial growth factor
 (VEGF), 204–205, 255, 267,
 See also anti-VEGF therapy
vascular permeability, 219–220,
 See also transfer constant K^{trans}
vascular proliferation, 209–210, 213,
 216
vascular space occupancy (VASO)
 imaging, 89–90
 acquisition parameters, 97
 analysis techniques, 95–96
 applications, 99–101
 experimental methods, 92–95
 iVASO, 113
 protocols, artifacts, limitations,
 96–99
 theory, 89–92
vascular system flow indicator, 2
vasculitis, 181–183
vasoconstriction, 184
vasodilatation, 144, 184, 304
vasodilators, 312
vasogenic edema, 214, 224
vasospasm, 128, 146–150, 181–183
vatalanib, 246
 v_e . *See* extravascular extracellular space
 (EES)
velocity-selective ASL (VS-ASL), 46
venous CBV (vCBV), 77–79, 82
venous output, 5–6
ventilation perfusion (V/Q),
 292
vessel size imaging, 31
volume of distribution (V), 283
von Hippel–Lindau syndrome, 226

wash-in rate, 256, 262
washout curve, 257–259, 262
washout percentage-enhancement
 difference, 258–259
washout rate, 259
washout rate constant k_{ep} , 261,
 267–268
Weinmann plasma curve, 68
Wiener filter, 30
wraparound artifacts, 271

xenon inhalation technique, 12
xenon-CT, 8–9, 129
X-ray mammography, 240, 260

zebra artifacts, 271